Sign In
Buy ENLV
$0.611
-0.0122 (-1.96%)
At Close: Jun 23, 2026
Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings
12:54pm, Monday, 22'nd Mar 2021
Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tum
-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therap
Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased ma
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
05:21pm, Friday, 12'th Feb 2021
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patient
ENLV Stock Price Falls Over 13% Pre-Market: Why It Happened
09:17am, Wednesday, 10'th Feb 2021
The stock price of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) fell over 13% pre-market as of 9:11 AM ET.
Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
11:25pm, Tuesday, 09'th Feb 2021
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patient
Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
05:25pm, Tuesday, 09'th Feb 2021
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patient
Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
08:00am, Monday, 11'th Jan 2021
Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced tha
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
08:00am, Monday, 21'st Dec 2020
– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and e
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
08:00am, Thursday, 03'rd Dec 2020
Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of an
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
08:00am, Wednesday, 18'th Nov 2020
* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of Directors
08:18am, Tuesday, 17'th Nov 2020
* Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright's 6th Annual Israel Conference
08:14am, Wednesday, 11'th Nov 2020
Nes Ziona, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the clini
Nes-Ziona, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trade
